ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have
advanced cancer of the pancreas.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Ionis Pharmaceuticals, Inc. National Cancer Institute (NCI)